The clinical development of tamoxifen was not a preplanned program by ICI Pharmaceuticals Division [10], but for me as a pharmacologist, it was “an objective ahead of its time.” We had a target in the tumor—the estrogen receptor (ER) [15–17]. The gene discussed is ESR1; the disease is neoplasm.